AZN

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
Search

Funds

AZN

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
Search

Funds

AZN

FTSE 100

Funds